Skip to main content
SleepCited

타우린 관련 입면 장애

B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.

Taurine의 glycine 및 GABA 수용체 작용은 수면 시작을 향한 신경화학적 전환을 촉진하는 데 도움이 될 수 있습니다. 한 소규모 임상 연구에서 취침 전 taurine 보충이 주관적 입면 시간을 줄인 것으로 나타났습니다. 전임상 데이터는 수면 촉진에서의 역할을 지지하지만, 더 큰 규모의 인체 시험이 필요합니다.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Dtaurine\u0026condition\u003Dsleep\u002Donset\u002Dlatency'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

결론

Taurine의 glycine 및 GABA 수용체 작용은 수면 시작을 향한 신경화학적 전환을 촉진하는 데 도움이 될 수 있습니다. 한 소규모 임상 연구에서 취침 전 taurine 보충이 주관적 입면 시간을 줄인 것으로 나타났습니다. 전임상 데이터는 수면 촉진에서의 역할을 지지하지만, 더 큰 규모의 인체 시험이 필요합니다.

Key Study Findings

Controlled Clinical Trial n=32 12 weeks Open-label
Efficacy and associated neurotransmitters of digital cognitive behavior therapy for atopic dermatitis: A comparative effectiveness …
Dose: None vs: Standard care alone Outcome: Itch and insomnia improvement in atopic dermatitis 효과: None 0.0449 (itch), 0.0089 (insomni

대상 집단: Patients with atopic dermatitis and mild-moderate negative emotions

Other
Energy drinks in Tamale: Understanding youth perceptions, consumption patterns, and related factors.
Dose: None vs: None Outcome: None 효과: None p < .05

대상 집단: Insomnia patients

Review
Commonly encountered symptoms and their management in patients with cirrhosis.
Dose: None vs: None Outcome: Pain outcomes 효과: None None

대상 집단: Insomnia patients

Observational Study
[Energy drink consumption patterns and its adverse effects on adolescent health.].
Dose: None vs: None Outcome: Energy drink consumption and adverse effects 효과: None None

대상 집단: Adolescents

Other
[Establishment of rat heart-kidney insomnia model consistent with traditional Chinese medicine syndrome and its serum …
Dose: None vs: None Outcome: rat model of cardiorenal insomnia from in vitro … 효과: None None

대상 집단: None

Review
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: insomnia patients

Key Statistics

9

연구

32

참여자

Mixed

B

등급

Referenced Papers

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

sleep:
500-2,000 mg, 1 hour before bed

상한량: 3,000 mg/day considered safe in clinical studies

연구에서 사용된 용량

용량 기간 효과 N
None 12 weeks Positive 32
None -- Neutral --
None -- Neutral --
None -- Mixed --
None -- Mixed --
None -- Positive --
None -- Positive --
None -- Mixed --

권장 복용 시간: 1 hour before bed

Safety & Side Effects

보고된 부작용

  • Generally well tolerated
  • Mild GI discomfort at high doses
  • Drowsiness (desired for sleep use)

알려진 상호작용

  • Lithium — taurine may alter lithium excretion
  • Antihypertensives — may have additive blood pressure lowering effects
  • CNS depressants — potential additive sedative effects

일일 최대 섭취 허용량: 3,000 mg/day considered safe in clinical studies

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does 타우린 help with 입면 장애?
Based on 9 studies with 32 participants, there is moderate evidence from clinical studies that 타우린 may support 입면 장애 management. Our evidence grade is B (Good Evidence).
How much 타우린 should I take for 입면 장애?
Studies have used various dosages. A commonly studied range is 500-2,000 mg, 1 hour before bed. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 타우린?
Reported side effects may include Generally well tolerated, Mild GI discomfort at high doses, Drowsiness (desired for sleep use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 타우린 and 입면 장애?
We rate the evidence as Grade B (Good Evidence). This rating is based on 9 peer-reviewed studies with 32 total participants. The overall direction of effect is mixed.

References

  1. [1] Wanying Zhai et al.. Asian Pac J Allergy Immunol. 2025. Efficacy and associated neurotransmitters of digital cognitive behavior therapy for atopic dermatitis: A comparative effectiveness research. doi:10.12932/AP-100223-1542 PubMed
  2. [2] Williams Kobik et al.. PLoS One. 2024. Energy drinks in Tamale: Understanding youth perceptions, consumption patterns, and related factors. doi:10.1371/journal.pone.0289391 PubMed
  3. [3] Cyriac Abby Philips. Front Med (Lausanne). 2024. Commonly encountered symptoms and their management in patients with cirrhosis. doi:10.3389/fmed.2024.1442525 PubMed
  4. [4] Paola Silva Maldonado et al.. Rev Esp Salud Publica. 2022. [Energy drink consumption patterns and its adverse effects on adolescent health.]. PubMed
  5. [5] Yu-Han Yang et al.. Zhongguo Zhong Yao Za Zhi. 2020. [Establishment of rat heart-kidney insomnia model consistent with traditional Chinese medicine syndrome and its serum metabolomics]. doi:10.19540/j.cnki.cjcmm.20190524.502 PubMed
  6. [6] Kirk J Brower. Alcohol. 2015. Assessment and treatment of insomnia in adult patients with alcohol use disorders. doi:10.1016/j.alcohol.2014.12.003 PubMed
  7. [7] Nicola J Kalk et al.. Br J Clin Pharmacol. 2014. The clinical pharmacology of acamprosate. doi:10.1111/bcp.12070 PubMed
  8. [8] Bhanu Prakash Kolla et al.. Alcohol Alcohol. 2011. Pharmacological treatment of insomnia in alcohol recovery: a systematic review. doi:10.1093/alcalc/agr073 PubMed
  9. [9] Kevin A Clauson et al.. J Am Pharm Assoc (2003). 2008. Safety issues associated with commercially available energy drinks. doi:10.1331/JAPhA.2008.07055 PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.